Strategies for inactivation of viral and bacterial contaminants in blood and blood components

Laboratory Medicine

Volumn 32, Issue 3, 2001, Pages 156-160

  Ogedegbe, H O ^a   Renk, C M ^a  

^a FLORIDA GULF COAST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HYPERICIN; PEPSIN A;

BACTERIUM CONTAMINATION; BLOOD COMPONENT THERAPY; BLOOD FILTRATION; BLOOD STORAGE; BLOOD TRANSFUSION; CYTOMEGALOVIRUS INFECTION; HEAT TREATMENT; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS E VIRUS; HEPATITIS G VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS 1; PARVOVIRUS; PH; PHOTODYNAMIC THERAPY; RADIATION; REVIEW; SERODIAGNOSIS; VIRUS INACTIVATION;

BACTERIA (MICROORGANISMS); CYTOMEGALOVIRUS; GB VIRUS C/HEPATITIS G VIRUS; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS E VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN T-LYMPHOTROPIC VIRUS 1; PARVOVIRUS;

EID: 0035148757     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/C2VD-X9A5-2W6H-DP48     Document Type: Review

References (40)

1. Blood collections by community blood centers, 1988 through 1992
2. Evaluation of a confidential method of excluding blood donors exposed to human immunodeficiency virus: Studies on hepatitis and cytomegalovirus markers
3. Transfusion medicine: An overview and update
4. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates
5. Solvent/detergent treatment of human plasma: A very robust method for virus inactivation: Validated virus safety of OCTAPLAS
6. The risk of transfusion-transmitted viral infections
7. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation
8. The epidemiology of virus transmission by plasma derivatives: Clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1
9. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma
10. Longitudinal monitoring of WBC subsets in packed RBC units after filtration: Implication for transfusion transmission of infections
11. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: Parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses
12. Viral safety of solvent/detergent-treated plasma
13. Inactivation of hepatitis A virus in plasma products by vapor heating
14. Viral safety of blood derivatives by immune neutralization
15. The use of tri(butyl)phosphate detergent mixture to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation
16. Effect of blood transfusion on subsequent kidney transplants
17. The effect of unmodified or prestorage white cell-reduced allogeneic red cell transfusion on the immune responsiveness in orthopedic surgery patients
18. Immune response to blood transfusion in very-low-birthweight infants
19. Immunologic changes after transfusion of autologus or allogeneic buffy coat-poor white cell reduced blood to patients undergoing arthroplasty, I: Proliferative T-cell responses and the balance of helper and suppressor T cells
20. Transfusion of buffy coat depleted blood components and risk of postoperative infection in orthopedic patients
21. Immunomodulation by blood transfusion: An evolving scientific and clinical challenge
22. Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage
23. Periodic alternating interphase positioning to lower WBC contamination of apheresis platelet concentrates: A multicenter evaluation
24. Removal of anaphylatoxins C3a and C5a and chemokines interleukin 8 and RANTES by polyester white cell-reduction and plasma filters
25. Evaluation of pooled platelet concentrates using prestorage versus poststorage WBC reduction: Impact of filtration timing
26. Universal leukoreduction: Fix or folly?
27. Effects of UVB radiation on cytokine generation, cell adhesion molecules, and cell activation markers in T-lymphocytes and peripheral blood HPCs
28. The induction of partial resistance to photodynamic therapy by the protooncogene BCL-2
29. Importance of type I and type II mechanisms in the photodynamic inactivation of viruses in blood with aluminum phthalocyanine derivatives
30. Inactivation of viruses in blood with aluminum phthalocyanine derivatives
31. What future means to management of blood centers
32. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psolaren plus UVA
33. Low risk of viral infection after administration of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of blood components
34. Transmission of parvovirus B 19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization
35. Effect of virucidal heat treatment on proteins in human factor VIII concentrates
36. Virus inactivation by pepsin treatment at pH 4 of IgG solutions: Factors affecting the rate of virus inactivation
37. Hypericin as an inactivator of infectious viruses in blood components
38. Inactivation of viruses in labile blood derivatives, I: Disruption of lipid-enveloped viruses by th(n-butyl)phosphate detergent combinations